StreetInsider.com News Articles

Needham Starts Evommune Inc (EVMN) at Buy

Wed, 26 Aug 2026 06:20:24 -0400

Needham analyst Serge Belanger initiates coverage on Evommune Inc (NYSE: EVMN) with a Buy rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $13.79 yesterday.

Form SCHEDULE 13G/A Evommune, Inc. Filed by: Andera Partners

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931186.html

Form SCHEDULE 13G/A Evommune, Inc. Filed by: Andera Partners

Fri, 14 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26931186.html

Form SCHEDULE 13G Evommune, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926612.html

Form SCHEDULE 13G Evommune, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 14 Aug 2026 10:39:00 -0400

si-local-file:///var/storage/secattach/20260814/26926612.html

Evommune, Inc. (EVMN) Misses Q2 EPS by 20c

Fri, 07 Aug 2026 16:20:00 -0400

Evommune, Inc. (NYSE: EVMN) reported Q2 EPS of ($0.89), $0.20 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Evommune, Inc. (EVMN) click here.

Evommune Inc (EVMN) PT Lowered to $29 at RBC Capital

Fri, 07 Aug 2026 07:20:57 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Evommune Inc (NYSE: EVMN) to $29.00 (from $30.00) while maintaining a Outperform rating.

Form 424B3 Evommune, Inc.

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26884025.html

Form 424B3 Evommune, Inc.

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26884025.html

Form 10-Q Evommune, Inc. For: Jun 30

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883898.html

Form 10-Q Evommune, Inc. For: Jun 30

Thu, 06 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260806/26883898.html

Form 8-K Evommune, Inc. For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883720.html

Form 8-K Evommune, Inc. For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883720.html

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)-- Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Thu, 06 Aug 2026 16:05:00 -0400

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027

‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference

‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline